北海康成-B(01228)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01228 北海康成-B

已收盘 09-21 15:48:15

1.960

-0.045

-2.24%

最高2.050	最低1.915	成交量51.90万
今开2.000	昨收2.005	日振幅6.73%
总市值11.72亿	流通市值11.72亿	总股本5.98亿
成交额102.48万	换手率0.09%	流通股本5.98亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01228","market":"HK","secType":"STK","nameCN":"北海康成-B","latestPrice":1.96,"timestamp":1789976895587,"preClose":2.005,"halted":0,"volume":519000,"delay":0,"changeRate":-0.02244389027431418,"floatShares":598000000,"shares":598000000,"eps":0.03,"marketStatus":"已收盘","change":-0.045,"latestTime":"09-21 15:48:15","open":2,"high":2.05,"low":1.915,"amount":1024770,"amplitude":0.067332,"askPrice":1.98,"askSize":13000,"bidPrice":1.96,"bidSize":10000,"shortable":0,"etf":0,"ttmEps":-0.157,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790040600000},"marketStatusCode":5,"adr":0,"listingDate":1639065600000,"exchange":"SEHK","adjPreClose":2.005,"openAndCloseTimeList":[[1789954200000,1789963200000],[1789966800000,1789977600000]],"volumeRatio":2.821839,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01228","defaultTab":"news","newsList":[{"id":"1163533564","title":"北海康成-B更新2026年8月股份变动月报表，新增280,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1163533564","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163533564?lang=zh_cn&edition=full","pubTime":"2026-09-07 16:36","pubTimestamp":1788770195,"startTime":"0","endTime":"0","summary":"北海康成製藥有限公司于2026年9月7日发布截至2026年8月31日的股份变动月报表。北海康成製藥有限公司目前的注册股本维持在5,000,000,000股普通股，每股面值0.00001美元，注册股本总额维持50,000美元。报告期内，公司因首次公开发售后购股权计划共有280,000股普通股被行使并发行。另外，首次公开发售前股权激励计划本月并未发生新股发行或库藏股转让，目前尚有20,643,860股可于该计划项下发行或转让。截至2026年8月31日，发行人股本总数小幅上升至597,723,347股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106148116","title":"北海康成-B更新8月股份变动月报，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1106148116","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106148116?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:16","pubTimestamp":1788513406,"startTime":"0","endTime":"0","summary":"北海康成製藥有限公司于2026年9月4日披露2026年8月股份变动月报。报告显示，截至2026年8月31日，公司注册股本继续保持5,000,000,000股，面值每股0.00001美元，注册股本总额50,000美元未发生变动。上述限制性股份单位所对应股份的实际流通量将根据后续激励计划条款逐步落实。本月未出现新购回或注销股份情形。公司确认已符合适用的香港联交所公众持股量要求，公告由董事长薛群博士签署。公司方面表示将继续遵守香港联交所《上市规则》及相关法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663024958","title":"北海康成：上半年亏损3710万元，收入同比增25.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663024958","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663024958?lang=zh_cn&edition=full","pubTime":"2026-08-31 12:42","pubTimestamp":1788151320,"startTime":"0","endTime":"0","summary":"8月31日，北海康成（01228）发布中期业绩公告，截止至2026年6月30日止六个月，公司的收益为2790万元，较2025年同期的2220万元增加25.6%。主要增长源自于Hunterase与迈芮倍的销售增长。其他收入及收益大幅减少，从1.04亿元下降至1130万元，主要由于前期美国租赁终止产生的收益减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313859928572.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313859928572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180975724","title":"北海康成-B2026年中期财报：营收27.9百万元，经调整净利润-28.2百万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1180975724","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180975724?lang=zh_cn&edition=full","pubTime":"2026-08-31 12:32","pubTimestamp":1788150745,"startTime":"0","endTime":"0","summary":"2026年上半年，北海康成-B实现营收27.9百万元，同比增长25.6%。经调整净利润为-28.2百万元，相比去年同期的-37.4百万元减亏约9.1百万元。毛利率从上年同期的69.3%下降至66.8%。主要成本结构中，研发费用12.5百万元，同比下降30.5%；销售及分销费用30.9百万元，同比上升36.3%；行政开支23.3百万元，同比上升40.3%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"北海康成-B2026年中期财报：营收27.9百万元，经调整净利润-28.2百万元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662430066","title":"北海康成-B(01228.HK)发布中期业绩 股东应占亏损3921.8万元 同比盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2662430066","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662430066?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:52","pubTimestamp":1787910751,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191858232","title":"北海康成-B（01228）2026年上半年营收27.9百万元，经调整净亏损28.2百万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191858232","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191858232?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:36","pubTimestamp":1787909784,"startTime":"0","endTime":"0","summary":"2026年上半年，北海康成-B实现营收27.9百万元，同比增加25.6%。期内经调整净亏损28.2百万元，相较上一年同期的37.4百万元下降24.3%。报告期内毛利为18.7百万元，对应毛利率66.8%。销售及分销开支扩大至30.9百万元，同比上升36.3%，主要投入在戈芮宁的商用推广，以及由自营转为合同销售模式所产生的一次性支出。戈谢病酶替代疗法戈芮宁已识别42名患者，并在40个城市纳入惠民保，覆盖1.75亿人口。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"北海康成-B（01228）2026年上半年营收27.9百万元，经调整净亏损28.2百万元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660437004","title":"北海康成-B(01228)：迈芮倍®获台湾健保署核准纳入健保支付","url":"https://stock-news.laohu8.com/highlight/detail?id=2660437004","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660437004?lang=zh_cn&edition=full","pubTime":"2026-08-18 06:34","pubTimestamp":1787006093,"startTime":"0","endTime":"0","summary":"智通财经APP讯，北海康成-B 发布公告，用于治疗阿拉杰里综合征与进行性家族性肝内胆汁淤积症的迈芮倍已获台湾健保署核准纳入健保支付，相关健保支付将于2026年9月1日正式生效。公司认为，迈芮倍是台湾地区首个获批用于治疗ALGS与PFIC的治疗药物，两项适应症同步纳入台湾健保支付，是当地患者的重大利好，也是公司罕见病商业化布局的重要里程碑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481114.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136894414","title":"北海康成-B（01228）“迈芮倍®”纳入台湾健保　覆盖ALGS与PFIC自2026年9月1日起生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1136894414","media":"公告速递","labels":["policyRegulatory","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136894414?lang=zh_cn&edition=full","pubTime":"2026-08-18 06:16","pubTimestamp":1787004970,"startTime":"0","endTime":"0","summary":"北海康成-B8月18日发布自愿公告称，其产品迈芮倍已获台湾中央健康保险署核准纳入健保支付，适用适应症为阿拉杰里综合征和进行性家族性肝内胆汁淤积症。相关健保支付将于2026年9月1日正式生效。根据公告，迈芮倍已在中国内地、中国香港、美国、欧盟及台湾地区获批，用于治疗不同月龄段ALGS与PFIC患者的胆汁淤积性瘙痒。公司表示，迈芮倍成为台湾地区首个同时覆盖ALGS与PFIC的健保支付药物，为本集团在罕见病商业化布局中取得重要进展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660436595","title":"北海康成－Ｂ(01228.HK)拟8月28日举行董事会会议以批准中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2660436595","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660436595?lang=zh_cn&edition=full","pubTime":"2026-08-17 23:07","pubTimestamp":1786979230,"startTime":"0","endTime":"0","summary":"格隆汇8月17日丨北海康成－Ｂ(01228.HK)宣布，公司将于2026年8月28日(星期五)举行董事会会议，藉以(其中包括)考虑及批准公司及其附属公司截至2026年6月30日止六个月的未经审计中期业绩及其发布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260817/32337751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198777098","title":"北海康成-B（01228）拟于8月28日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1198777098","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198777098?lang=zh_cn&edition=full","pubTime":"2026-08-17 22:31","pubTimestamp":1786977112,"startTime":"0","endTime":"0","summary":"北海康成-B（01228）8月17日在港交所公告称，公司董事会将于2026年8月28日（星期五）召开会议，审议并批准公司及其附属公司截至2026年6月30日止六个月的未经审计中期业绩及其发布事宜。\n公告显示，截至公告日期，公司董事会成员包括：执行董事薛群博士；非执行董事赵玮女士、王廷伟先生；以及独立非执行董事Dr. Richard Arthur Moscicki、James Arthur Geraghty、陈炳钧先生及胡澜博士。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105365375","title":"北海康成-B 2026年7月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1105365375","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105365375?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:41","pubTimestamp":1786005698,"startTime":"0","endTime":"0","summary":"2026年8月6日，北海康成製藥有限公司公布截至2026年7月31日止月份的证券变动月报表。公告显示，公司本月未新增发行、购回或注销股份，股本结构整体维持稳定。报告期内的法定/注册股本维持在5,000,000,000股，面值为每股0.00001美元，注册股本总额约为50,000美元。根据公告，北海康成-B的首次公开发售后购股权计划在月末结存的股份期权数量为19,798,637份。北海康成-B表示将继续严格遵守香港联交所《上市规则》及其他相关法规规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657071571","title":"北海康成-B(01228.HK)：Richard Arthur Moscicki获委任为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2657071571","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657071571?lang=zh_cn&edition=full","pubTime":"2026-08-06 06:19","pubTimestamp":1785968393,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01228","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167564454","title":"北海康成-B（01228）公布董事会及三大专门委员会组成","url":"https://stock-news.laohu8.com/highlight/detail?id=1167564454","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167564454?lang=zh_cn&edition=full","pubTime":"2026-08-06 06:16","pubTimestamp":1785968212,"startTime":"0","endTime":"0","summary":"2026年8月5日，北海康成制药有限公司披露董事名册及董事在各专门委员会中的职能分工。本次公告未包含任何财务数据或业务经营指标。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143484451","title":"北海康成-B（01228）：独立董事调整，Richard Arthur Moscicki 8月5日加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1143484451","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143484451?lang=zh_cn&edition=full","pubTime":"2026-08-06 06:10","pubTimestamp":1785967839,"startTime":"0","endTime":"0","summary":"\\n\\n公司同日宣布，Richard Arthur Moscicki 博士获委任为独立非执行董事、薪酬委员会主席及审核委员会成员，生效日期同为2026年8月5日。\\n\\n根据服务协议，Moscicki 博士任期自生效日起至公司下届股东周年大会届满，届时可按公司组织章程细则获重选连任；若重选成功，任期将再延续三年。\\n\\n截至公告日，公司董事会由执行董事薛群博士；非执行董事赵瑋女士、王廷伟先生；独立非执行董事Richard Arthur Moscicki 博士、James Arthur Geraghty先生、陈炳钧先生及胡澜博士组成。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123773592","title":"北海康成-B特别股东大会普通决议案获全票通过","url":"https://stock-news.laohu8.com/highlight/detail?id=1123773592","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123773592?lang=zh_cn&edition=full","pubTime":"2026-08-03 18:22","pubTimestamp":1785752576,"startTime":"0","endTime":"0","summary":"北海康成-B8月3日公告，2026年8月3日举行的股东特别大会已全票通过一项普通决议案，同意批准、追认及确认与药明生物签订的服务采购框架协议及其年度上限，并授权董事办理相关事宜。投票结果显示，赞成票201,307,108股，占出席并有表决权股份的100%；反对票0股，占比0%。其中，药明生物间接持有96,859,693股，占已发行股本约16.21%，并已按上市规则在会议中放弃投票。因此，本次可投票股份总数为500,583,654股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655820269","title":"北海康成-B：戈芮宁出海北非市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2655820269","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655820269?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:47","pubTimestamp":1785404820,"startTime":"0","endTime":"0","summary":"7月30日，北海康成-B（01228）发布公告，公司已全面启动戈芮宁（注射用维拉苷酶β）在北非市场的注册程序及商业化准备工作。戈芮宁于2025年5月15日获得中国国家药品监督管理局的上市批准，成为中国首个本土自主研发的I型及III型戈谢病患者的长期酶替代疗法。戈芮宁出海北非市场是布局全球戈谢病市场的重要里程碑，预计将提高北非患者的治疗可及性，并丰富公司的收益结构。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607303826811957.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607303826811957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01228","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184078591","title":"北海康成-B启动戈芮寧出海北非注册与商业化准备","url":"https://stock-news.laohu8.com/highlight/detail?id=1184078591","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184078591?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:26","pubTimestamp":1785403575,"startTime":"0","endTime":"0","summary":"北海康成-B（01228）7月30日公告称，已全面启动旗下自主研发产品戈芮寧（注射用维拉苷酶β）在北非重点市场的注册程序及商业化筹备工作，相关上市准备正有序推进。\n戈芮寧已于2025年5月15日获中国国家药品监督管理局批准上市，适用于12岁及以上青少年与成人I型及III型戈谢病患者的长期酶替代疗法。该产品为中国首个本土自主研发的同类疗法，北海康成-B拥有其全球开发及商业化专有权利。\n公司正进行一项获国家药监局批准的注册临床试验，计划将戈芮寧的适用人群扩展至2岁至12岁儿童。\n截至公告日期，公司尚未在北非市场录得戈芮寧的正式销售收益，相关卫生监管机构的注册程序仍在进行中。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192558564","title":"北海康成-B启动戈润在非洲北部市场的注册及上市筹备工作","url":"https://stock-news.laohu8.com/highlight/detail?id=1192558564","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192558564?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:24","pubTimestamp":1785403484,"startTime":"0","endTime":"0","summary":"北海康成-B正式宣布，已着手启动戈润产品于北非市场的注册流程与上市准备工作。这一战略举措标志着该公司正加速布局海外新兴市场。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655827576","title":"北海康成-B(01228.HK)已全面启动戈芮宁于北非重点市场的注册程序及商业化筹备工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2655827576","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655827576?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:23","pubTimestamp":1785403383,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174725577","title":"北海康成-B（01228）将于2026年8月3日线上召开股东特别大会审议与药明生物服务采购框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1174725577","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174725577?lang=zh_cn&edition=full","pubTime":"2026-07-15 22:22","pubTimestamp":1784125344,"startTime":"0","endTime":"0","summary":"北海康成-B7月15日公告，公司拟于2026年8月3日09:00以线上方式召开股东特别大会，就与药明生物有关的服务采购框架协议及其年度上限进行审批、追认及确认，并授权董事会成员办理相关事宜。\\n\\n根据公告，股东如欲在股东特别大会上行使表决权，须通过委任大会主席为受委代表并在指定时限内递交代表委任表格。以印刷或电子形式提交代表委任表格的截止时间均为2026年8月1日09:00。凡于2026年8月3日名列股东名册的股东，有权出席并投票。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ssitimber.com.hk","stockEarnings":[{"period":"1week","weight":0.0553},{"period":"1month","weight":-0.0172},{"period":"3month","weight":0.0075},{"period":"6month","weight":-0.2462},{"period":"1year","weight":-0.2318},{"period":"ytd","weight":-0.2168}],"compareEarnings":[{"period":"1week","weight":-0.0022},{"period":"1month","weight":-0.0292},{"period":"3month","weight":0.0345},{"period":"6month","weight":-0.0208},{"period":"1year","weight":-0.0676},{"period":"ytd","weight":-0.0343}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"CANbridge Pharmaceuticals Inc是一家全球生物制药公司。该公司专注于罕见病转化疗法的研究、开发和商业化。该公司拥有一个药物组合，其中包括三种获批药物和八种资产的管线，针对尚未满足需求的罕见病适应症。这些包括亨特综合征和其他溶酶体贮积症、阵发性睡眠性血红蛋白尿和其他补体介导的疾病、血友病A、代谢性疾病、罕见胆汁淤积性肝病和神经肌肉疾病。其管线包括Hunterase、Livmarli、CAN106和CAN103。Hunterase是一种酶替代疗法，用于治疗II型粘多糖贮积症（MPS II），也称为亨特综合征。Livmarli是一种口服、吸收率极低、可逆性的回肠胆汁酸转运蛋白抑制剂，正在开发中，用于治疗罕见的胆汁淤积性肝病，包括Alagille综合征和进行性家族性肝内胆汁淤积症。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.126185},{"month":2,"riseRate":0.4,"avgChangeRate":0.011895},{"month":3,"riseRate":0.2,"avgChangeRate":-0.095239},{"month":4,"riseRate":0.2,"avgChangeRate":-0.054254},{"month":5,"riseRate":0,"avgChangeRate":-0.09989},{"month":6,"riseRate":0.4,"avgChangeRate":0.271134},{"month":7,"riseRate":0.4,"avgChangeRate":0.385009},{"month":8,"riseRate":0.2,"avgChangeRate":0.187363},{"month":9,"riseRate":0.8,"avgChangeRate":0.13538},{"month":10,"riseRate":0,"avgChangeRate":-0.161874},{"month":11,"riseRate":0.25,"avgChangeRate":-0.205763},{"month":12,"riseRate":0.5,"avgChangeRate":0.059277}],"exchange":"SEHK","name":"北海康成-B","nameEN":"CANBRIDGE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"北海康成-B(01228)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供北海康成-B(01228)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"北海康成-B,01228,北海康成-B股票,北海康成-B股票老虎,北海康成-B股票老虎国际,北海康成-B行情,北海康成-B股票行情,北海康成-B股价,北海康成-B股市,北海康成-B股票价格,北海康成-B股票交易,北海康成-B股票购买,北海康成-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"北海康成-B(01228)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供北海康成-B(01228)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}